Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proteogenomic profiling uncovers differential therapeutic vulnerabilities between TCF3::PBX1 and TCF3::HLF translocated B-cell acute lymphoblastic leukemia.
Blumel L, Bernardi F, Picard D, Diaz JT, Jepsen VH, Hasselmann R, Schliehe-Diecks J, Bartl J, Qin N, Bornhauser B, Bhatia S, Marovka B, Marsaud V, Dingli F, Loew D, Stanulla M, Bourqin JP, Borkhardt A, Remke M, Ayrault O, Fischer U. Blumel L, et al. Among authors: borkhardt a. Haematologica. 2024 Feb 29. doi: 10.3324/haematol.2023.283928. Online ahead of print. Haematologica. 2024. PMID: 38426288 Free article.
Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
Sinatra L, Yang J, Schliehe-Diecks J, Dienstbier N, Vogt M, Gebing P, Bachmann LM, Sönnichsen M, Lenz T, Stühler K, Schöler A, Borkhardt A, Bhatia S, Hansen FK. Sinatra L, et al. Among authors: borkhardt a. J Med Chem. 2022 Dec 22;65(24):16860-16878. doi: 10.1021/acs.jmedchem.2c01659. Epub 2022 Dec 6. J Med Chem. 2022. PMID: 36473103
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V, Theruvath J, Pauck D, Picard D, Qin N, Blümel L, Maue M, Bartl J, Ahmadov U, Langini M, Meyer FD, Cole A, Cruz-Cruz J, Graef CM, Wölfl M, Milde T, Witt O, Erdreich-Epstein A, Leprivier G, Kahlert U, Stefanski A, Stühler K, Keir ST, Bigner DD, Hauer J, Beez T, Knobbe-Thomsen CB, Fischer U, Felsberg J, Hansen FK, Vibhakar R, Venkatraman S, Cheshier SH, Reifenberger G, Borkhardt A, Kurz T, Remke M, Mitra S. Marquardt V, et al. Among authors: borkhardt a. J Immunother Cancer. 2023 Jan;11(1):e005871. doi: 10.1136/jitc-2022-005871. J Immunother Cancer. 2023. PMID: 36639156 Free PMC article.
Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group.
Junk SV, Schaeffeler E, Zimmermann M, Möricke A, Beier R, Schütte P, Fedders B, Alten J, Hinze L, Klein N, Kulozik A, Muckenthaler MU, Koehler R, Borkhardt A, Vijayakrishnan J, Ellinghaus D, Forster M, Franke A, Wintering A, Kratz CP, Schrappe M, Schwab M, Houlston RS, Cario G, Stanulla M. Junk SV, et al. Among authors: borkhardt a. J Exp Clin Cancer Res. 2023 Jan 13;42(1):21. doi: 10.1186/s13046-022-02585-x. J Exp Clin Cancer Res. 2023. PMID: 36639636 Free PMC article.
Cytokine Hyperresponsiveness in Children With ETV6::RUNX1-positive Acute Lymphoblastic Leukemia After Challenge With Common Pathogens.
Rüchel N, Oldenburg M, Janssen S, Pandyra AA, Liu W, Vasileiou E, Hein D, Jepsen VH, Fischer U, Picard D, Kögler G, Hauer J, Auer F, Beer A, Adams O, MacKenzie C, Jaeger M, Netea MG, Borkhardt A, Gössling KL. Rüchel N, et al. Among authors: borkhardt a. Hemasphere. 2023 Jan 31;7(2):e835. doi: 10.1097/HS9.0000000000000835. eCollection 2023 Feb. Hemasphere. 2023. PMID: 36741356 Free PMC article. No abstract available.
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia.
Palmi C, Bresolin S, Junk S, Fazio G, Silvestri D, Zaliova M, Oikonomou A, Scharov K, Stanulla M, Moericke A, Zimmermann M, Schrappe M, Buldini B, Bhatia S, Borkhardt A, Saitta C, Galbiati M, Bardini M, Lo Nigro L, Conter V, Valsecchi MG, Biondi A, Te Kronnie G, Cario G, Cazzaniga G. Palmi C, et al. Among authors: borkhardt a. Hemasphere. 2023 May 26;7(6):e892. doi: 10.1097/HS9.0000000000000892. eCollection 2023 Jun. Hemasphere. 2023. PMID: 37304931 Free PMC article.
Worms on stage.
Pandyra AA, Borkhardt A. Pandyra AA, et al. Among authors: borkhardt a. Haematologica. 2023 Dec 1;108(12):3201-3203. doi: 10.3324/haematol.2023.283709. Haematologica. 2023. PMID: 37439330 Free PMC article. No abstract available.
Development of the first geldanamycin-based HSP90 degraders.
Wurnig S, Vogt M, Hogenkamp J, Dienstbier N, Borkhardt A, Bhatia S, Hansen FK. Wurnig S, et al. Among authors: borkhardt a. Front Chem. 2023 Jun 28;11:1219883. doi: 10.3389/fchem.2023.1219883. eCollection 2023. Front Chem. 2023. PMID: 37448856 Free PMC article.
Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors.
Stachura P, Liu W, Xu HC, Wlodarczyk A, Stencel O, Pandey P, Vogt M, Bhatia S, Picard D, Remke M, Lang KS, Häussinger D, Homey B, Lang PA, Borkhardt A, Pandyra AA. Stachura P, et al. Among authors: borkhardt a. Mol Cancer. 2023 Aug 15;22(1):136. doi: 10.1186/s12943-023-01833-8. Mol Cancer. 2023. PMID: 37582744 Free PMC article.
471 results